<DOC>
	<DOCNO>NCT00923130</DOCNO>
	<brief_summary>Background : - Substantial preclinical antitumor synergy support exploration combination antiangiogenic compound ( include sunitinib bevacizumab ) plus ixabepilone . In Vivo , synergistic activity ixabepilone bevacizumab demonstrate use 151-B human renal carcinoma xenograft model synergy compare favorably antiangiogenic inhibitor ( i.e . sunitinib ) . - Combination therapy bevacizumab chemotherapy demonstrate improved benefit compare single-agent cytotoxics multiple animal model human . - Clinical activity compound use single agent demonstrate broad spectrum solid tumor . Bevacizumab ixabepilone , use single agent , demonstrate substantial activity renal cell carcinoma . - Phase II study bevacizumab ixabepilone suggest absence overlap toxicity . - Development well-tolerated active bevacizumab/ixabepilone combination potential improve treatment metastatic renal cell carcinoma ( mRCC ) , could represent second-line option sunitinib sorafenib long benefit intolerable . Primary Objectives : - Determine objective response rate combination ixabepilone bevacizumab patient relapse refractory mRCC . - Determine progression-free survival . - Characterize toxicity combination ixabepilone bevacizumab patient mRCC . - Determine change biomarkers evaluate correlation clinical outcome . Eligibility : - Pathologic confirmation renal cell carcinoma ( clear cell histology ) Laboratory Pathology , NCI , Medical University South Carolina . - Presence metastatic renal carcinoma , progression intolerance VEGFR inhibitor ( sunitinib and/or sorafenib ) . - Adequate organ bone marrow function . Design : - Multi-center , open label phase II study - Following Simon two-stage optimal design , maximum 58 patient metastatic RCC accrued . - Ixabepilone administer daily one hour infusion five successive day ( daily x 5 ) , every three week ( one cycle equal 3 week 21 day +/- 5 day ) . Following cycle 6 , cycle spread 4 week 28 day +/- 5 day . The start dose daily dose 6 mg/m ( 2 ) /day , total per cycle dose 30 mg/m ( 2 ) . - In addition , 15 mg/kg bevacizumab administer intravenously day 1 cycle . The first infusion bevacizumab 90 minute duration , second 60 minute duration , subsequent cycle bevacizumab infused 30 minute prior infusion well tolerate .</brief_summary>
	<brief_title>Bevacizumab Plus Ixabepilone Treat Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>Background : - Substantial preclinical antitumor synergy support exploration combination antiangiogenic compound ( include sunitinib bevacizumab ) plus ixabepilone . In Vivo , synergistic activity ixabepilone bevacizumab demonstrate use 151-B human renal carcinoma xenograft model synergy compare favorably antiangiogenic inhibitor ( i.e . sunitinib ) . - Combination therapy bevacizumab chemotherapy demonstrate improved benefit compare single-agent cytotoxics multiple animal model human . - Clinical activity compound use single agent demonstrate broad spectrum solid tumor . Bevacizumab ixabepilone , use single agent , demonstrate substantial activity renal cell carcinoma . - Phase II study bevacizumab ixabepilone suggest absence overlap toxicity . - Development well-tolerated active bevacizumab/ixabepilone combination potential improve treatment metastatic renal cell carcinoma ( mRCC ) , could represent second-line option sunitinib sorafenib long benefit intolerable . Primary Objectives : - Determine objective response rate combination ixabepilone bevacizumab patient relapse refractory mRCC . - Determine progression-free survival . - Characterize toxicity combination ixabepilone bevacizumab patient mRCC . - Determine change biomarkers evaluate correlation clinical outcome . Eligibility : - Pathologic confirmation renal cell carcinoma ( clear cell histology ) Laboratory Pathology , NCI , Medical University South Carolina . - Presence metastatic renal carcinoma , progression intolerance VEGFR inhibitor ( sunitinib and/or sorafenib ) . - Adequate organ bone marrow function . Design : - Multi-center , open label phase II study - Following Simon two-stage optimal design , maximum 58 patient metastatic RCC accrued . - Ixabepilone administer daily one hour infusion five successive day ( daily x 5 ) , every three week ( one cycle equal 3 week 21 day +/- 5 day ) . Following cycle 6 , cycle spread 4 week 28 day +/- 5 day . The start dose daily dose 6 mg/m ( 2 ) /day , total per cycle dose 30 mg/m ( 2 ) . - In addition , 15 mg/kg bevacizumab administer intravenously day 1 cycle . The first infusion bevacizumab 90 minute duration , second 60 minute duration , subsequent cycle bevacizumab infused 30 minute prior infusion well tolerate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects meet follow criterion consider enrollment study : 1 . Pathologic confirmation metastatic unsectable renal cell carcinoma predominant clear cell histology ( great 70 % ) Laboratory Pathology , NCI Medical University South Carolina.. 2 . Progression stop treatment agent approve FDA treatment RCC . Patients must receive least one FDA approve agent ( axitinib , sunitinib , sorafenib , pazopanib , temsirolimus , IL2 , interferon everolimus ) . Patients must prior IL2 interferon 4 week prior entry . They must sunitinib , sorafenib , pazopanib , axitinib , temsirolimus everolimus TKIs 2 week prior entry . 3 . Eighteen year age old . 4 . ECOG performance status less equal 2 . 5 . Resolution toxic effect prior therapy ( except alopecia ) NCI CTCAE v.3.0 12/31/10 version 4.0 begin 1/1/11 grade less equal 1 baseline laboratory value define inclusion criterion # 6 . 6 . Adequate organ bone marrow function evidence : hemoglobin great equal 9.0 g/dL absolute neutrophil count great equal 1.5 x 10 ( 9 ) /L platelet count great equal 100 x 10 ( 9 ) /L creatinine less equal 1.5 time ULN , OR measure creatinine clearance great equal 40 ml/min urine proteinuria le 20mg/dL randon protein creatinine ratio urine sample 24hour urine protein le 500 mg . NOTE : If random protein creatinine ratio urine protein great equal 20mg/dL , obtain 24 hour urine collection accurately demonstrate 24 hour total le 500 mg/24 hour . AST/SGOT ALT/SGPT less equal 2.5 time ULN ( less equal 5 time ULN liver function abnormality due underlying malignancy ) total bilirubin less equal 1.5 time ULN 7 . Subjects must postmenopausal , surgically sterile , use effective contraception . All female subject childbearing potential must negative pregnancy test ( serum urine ) within 7 day prior enrollment . Effective contraception include hormonal barrier method . 8 . No invasive malignancy within past two year ( exception nonmelanoma skin cancer , noninvasive bladder cancer , stage I endometrial cancer cervical cancer ) . 9 . Subjects must agree sign date Institutional Review Board ( IRB ) approve subject informed consent form . 10 . Subjects must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 11 . Patients must measurable disease either conventional imaging clinical examination . EXCLUSION CRITERIA : Subjects present follow include study : 1 . Invasive procedure define follow : Major surgical procedure , open biopsy significant traumatic injury within 6 week prior Day 1 therapy Anticipation need major surgical procedure course study Minor surgery , portacath placement , dental procedure , within 2 week . ( There delay percutaneous core biopsy PICC/IJ line placement ) 2 . Cumulative radiation therapy great 25 % total bone marrow . 3 . History uncontrolled labile hypertension , define blood pressure great 160/90 mm Hg ( NCI CTCAE v.3.0 12/31/10 version 4.0 begin 1/1/11 grade great equal 2 ) , least 2 repeated determination separate day within 15 day prior study enrollment . 4 . Any follow within 6 month prior study enrollment : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure ; cerebrovascular accident transient ischemic attack , grade great equal 2 peripheral neuropathy , peptic ulcer disease , erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , thromboembolic event . 5 . Symptomatic spinal cord compression . 6 . Evidence clinically significant bleed diathesis underlie coagulopathy . 7 . Antiretroviral therapy HIV disease . 8 . Pregnant ( positive pregnancy test ) nursing woman . Both fertile men woman must agree use adequate contraceptive measure study therapy least 6 month completion bevacizumab therapy . 9 . Other severe acute chronic medical psychiatric condition , significant laboratory abnormality require investigation may cause undue risk subject safety , 18 inhibit protocol participation , interfere interpretation study result , judgment investigator would make subject inappropriate entry study . 10 . Prior therapy bevacizumab 11 . Prior therapy ixabepilone . 12 . Patients anticoagulant therapy evaluate case case basis inclusion . 13 . Serious nonhealing wound , ulcer bone fracture 14 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior day 1 15 . Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 16 . Known CNS disease except treated brain metastasis . Treated brain metastasis define ongoing requirement steroid evidence progression hemorrhage treatment least 3 month , ascertain clinical examination brain imaging ( MRI CT ) . ( Stable dose anticonvulsant allow ) . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . 17 . Patients know hypersensitivity Chinese hamster ovary cell product recombinant human antibody 18 . Patients receive CYP3A4 inhibitor section 3.6 discontinue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Ixabepilone</keyword>
	<keyword>Phase II</keyword>
</DOC>